From the INTERNATIONAL BUREAU

PCT

NOTIFICATION OF ELECTION

(PCT Rule 61.2)

Commissioner **US Department of Commerce United States Patent and Trademark** Office, PCT 2011 South Clark Place Room CP2/5C24

Arlington, VA 22202

ETATS-UNIS D'AMERIQUE

Date of mailing (day/month/year) 15 May 2001 (15.05.01)	ETATS-UNIS D'AMERIQUE in its capacity as elected Office
International application No.	Applicant's or agent's file reference
PCT/IL00/00494	38807
International filing date (day/month/year)	Priority date (day/month/year)
15 August 2000 (15.08.00)	19 August 1999 (19.08.99)
Applicant	<u> </u>
BLATT, Yoav et al	

1.	The designated Office is hereby notified of its election made:
	X in the demand filed with the International Preliminary Examining Authority on:
	02 February 2001 (02.02.01)
	in a notice effecting later election filed with the International Bureau on:
2.	The election X was
	was not
	made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland

Authorized officer

Claudio Borton

Telephone No.: (41-22) 338.83.38

Facsimile No.: (41-22) 740.14.35

PCT

NOTIFICATION OF DEFECTS IN DEMAND

(PCT Rule 60.1(d))

From the INTERNATIONAL BUREAU

Commissioner **US Department of Commerce** United States Patent and Trademark Office, PCT 2011 South Clark Place Room CP2/5C24

Arlington, VA 22202

ETATS-UNIS D'AMERIQUE

in its capacity as International Preliminary Examining Authority

Date of mailing

(day/month/year) 15 May 2001 (15.05.01)

International application No.

PCT/IL00/00494

International filing date

(day/month/year) 15 August 2000 (15.08.00)

Applicant

BIO DAR LTD. et al

The International Bureau hereby notifies the International Preliminary Examining Authority that it has found that the demand is defective for the reasons indicated below:
1. It does not contain the election of at least one Contracting State bound by Chapter II (Rule 53.2(a)(iv) and 53.7).
2. It does not permit the identification of the international application to which it relates (Rule 60.1(b)).
3. It does not contain the required petition (Rules 53.2(a)(i) and 53.3).
4. It does not contain the required indications concerning the agent as specified in the Annex (Rules 53.2(a)(ii) and 53.5).
5. It does not contain the required indications concerning the international application as specified in the Annex (Rules 53.2(a)(iii) and 53.6).
6. It is not submitted in the required language which is
7. It is not made on the printed form (Rule 53.1(a)).
8. It is presented as a computer print-out the particulars of which do not comply with the Administrative Instructions (Rule 53.1(a)).
9. It does not contain the required indications concerning the applicant as specified in the Annex (Rules 53.2(a)(ii) and 53.4).
10. X It does not contain the required signature as specified in the Annex (Rules 53.2(b) and 53.8).
Other observations, if necessary:

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland

Authorised officer

Claudio Borton

Telephone No.: (41-22) 338.83.38

NOTIFICATION C DEFECTS IN DEMAND

rational application No.

PCT/IL00/00494

Continuation of item 4: As to indications concerning the agent (Rule 4.4), the demand:
a. does not properly indicate the agent's name (specify):
h dans and indicate the country address.
bdoes not indicate the agent's address.
c. does not properly indicate the agent's address (specify):
Continuation of item 5: As to indications concerning the international application, the demand does not indicate:
a. the international filing date.
b. the international application number.
c. the name of the receiving Office, where the international application number was not known to the applicant at
the time the demand was filed.
d. the title of the invention.
Continuation of item 9: As to indications concerning the applicant (Rules 4.4 and 4.5), the demand:
adoes not indicate all the applicants for the elected States.
b. does not properly indicate the applicant's name (specify):
c. does not indicate the applicant's address.
d. does not properly indicate the applicant's address (specify):
e. does not indicate the applicant's nationality.
f. does not indicate the applicant's residence.
Continuation of item 10: As to requirements concerning signature (Rules 4.15 and 90.4), the demand:
a. is not signed.
b. is not signed by all the applicants for the elected States.
c. is not accompanied by the statement referred to in the check list in Box No. VI of the demand explaining the lack
of the signature of an applicant for the election of the United States of America.
d. X is signed by what appears to be an agent/common representative but
X the demand is not accompanied by a power of attorney appointing him. ZiELiNSKI, W.T.
the power of attorney accompanying the demand is not signed by all the applicants for the elected States.

PCT

NOTIFICATION CONCERNING AMENDMENTS OF THE CLAIMS

(PCT Rule 62 and Administrative Instructions, Section 417)

Date of mailing (day/month/year) 15 May 2001 (15.05.01)

International application No. PCT/IL00/00494

Applicant

BIO DAR LTD. et al

From the INTERNATIONAL BUREAU

10:

Commissioner
US Department of Commerce
United States Patent and Trademark
Office, PCT
2011 South Clark Place Room
CP2/5C24
Arlington, VA 22202
ETATS-UNIS D'AMERIQUE

in its capacity as International Preliminary Examining Authority

International filing date (day/month/year)
15 August 2000 (15.08.00)

The International Bureau hereby informs the International Preliminary Examining Authority that no amendments under Article 19 have been received by the International Bureau (Administrative Instructions, Section 417).

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland

Authorized officer

Claudio Borton

Telephone No. (41-22) 338.83.38

Facsimile No. (41-22) 740.14.35

PCT

	REC'D	13 NO	V	2001
L	WIPO		F	CT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

	,		
Applicant's or agent's file reference 6727/21239WO	FOR FURTHER ACTION	FION See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
International application No.	International filing date (day	v/month/year)	Priority date (day/month/year)
PCT/IL00/00494	15 AUGUST 2000		(NONE) 19 Aug 1999
International Patent Classification (IPC) Please See Supplemental Sheet.	or national classification and	IPC	
Applicant BIO DAR LTD.			
Examining Authority and is 2. This REPORT consists of a This report is also accompanded and are the	transmitted to the applicant total of sheets. panied by ANNEXES, i.e., slee basis for this report and or so no 607 of the Administrative	nt according to neets of the desc sheets containin	rription, claims and or drawings which have g rectifications made before this Authority.
3. This report contains indication		items:	
I X Basis of the report II Priority III X Non-establishmen IV Lack of unity of V X Reasoned statemen citations and explain VI Certain documents of VII Certain defects in the	nt of report with regard to invention t under Article 35(2) with re nations supporting such state	novelty, invent gard to novelty, ment	tive step or industrial applicability
Date of submission of the demand O2 FEBRUARY 2001	Da	10 OCTOBER	·
Name and mailing address of the IPEA/ Commissioner of Patents and Tradem Box PCT Washington, D.C. 20231	1 1	thorized officer	Budgestin
Facsimile No. (703) 305-3230	π(ε	Tephone No.	(703) 308-1235



International application No.

PCT/IL00/00494

I. B	asis of th	e report		
1 With	regard to	the elements of the internat	ional application:*	
	-	national application as		
님	the desc			
X	pages _	•		, as originally filed
	pages _			, filed with the demand
	pages _		, filed with the letter of	
X	the clair	16.10		as saisimally filed
	pages _		, as amended (together with an	, as originally filed
	pages _			, filed with the demand
	pages _ pages _	NONE	, filed with the letter of	, med with the demand
	Pages _		, , , , , , , , , , , , , , , , , , , ,	
X	the drav	vings:		
لتتا	pages _	NONE		, as originally filed
	pages _			, filed with the demand
	pages _	NONE	, filed with the letter of	
X	_	ence listing part of the de		ininally filed
	pages _	NONE		, as originally filed
	pages _	NONE	, filed with the letter of	, filed with the demand
	pages _	NONE	, theu with the letter of	
	the lang	uage of publication of the	nished for the purposes of international search the international application (under Rule 48.3(l ished for the purposes of international preliminary	b)).
			amino acid sequence disclosed in the internation out on the basis of the sequence listing:	onal application, the international
	containe	d in the international ar	oplication in printed form.	
		//	onal application in computer readable form.	
片	_			
님			authority in written form.	
Ш		• • •	authority in computer readable form.	
	internation	onal application as filed b		
	The state been fun		recorded in computer readable form is identical to	the writen sequence listing has
4. X	The am	endments have resulted	in the cancellation of:	
٠	\overline{X} ,	a description pages	NONE	
	₩ 	e description, pages	NONE	
		e claims, Nos.		
		e drawings, sheets /fig	· · · · · · · · · · · · · · · · · · ·	
5.			ome of) the amendments had not been made, since	
in t	lacement s	heets which have been furn	indicated in the Supplemental Box (Rule 70.2(c)).** ished to the receiving Office in response to an invitati are not annexed to this report since they do not	ion under Article 14 are referred to
		nent sheet containing such	amendments must be referred to under item 1 ar	nd annexed to this report.

International application No. PCT/IL00/00494

III. N	on-establishment of opinion with regard to novelty, inventive step and industrial applicability
	questions whether the claimed invention appears to be novel, to involve an inventive step (to be non obvious), or to be trially applicable have not been and will not be examined in respect of:
	the entire international application.
X	claims Nos. <u>15-32</u>
	because:
	the said international application, or the said claim Nos. relate to the following subject matter which does not require international preliminary examination (specify).
	·
	·
	the description, claims or drawings (indicate particular elements below) or said claims Nos. are so unclear that no meaningful opinion could be formed (specify).
	-
	the claims, or said claims Nos are so inadequately supported by the description that no meaningful opinion could be formed.
X	no international search report has been established for said claims Nos. 15-32.
	aningful international preliminary examination cannot be carried out due to the failure of the nucleotide and/or amino acid nee listing to comply with the standard provided for in Annex C of the Administrative Instructions:
	the written form has not been furnished or does not comply with the standard.
	the computer readable form has not been furnished or does not comply with the standard.

International application No.

PCT/IL00/00+9+

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicable citati in and explanations supporting such statement Novelty (N) Claims Claims Inventive Step (IS) Claims Claims Claims Industrial Applicability (IA) Claims Claims Claims Industrial Applicability (IA) Claims Claims Industrial Applicability (IA) Claims Claims Interpolation of Claims Claims Interpolation of Claims Inter	
Inventive Step (IS) Claims Claims Claims Claims Claims Claims Claims Industrial Applicability (IA) Claims Claims Claims Claims Claims Claims Claims Industrial Applicability (IA) Claims Claims Claims Claims Claims Claims Industrial Applicability (IA) Claims Claims Claims Industrial Applicability (IA) Claims Claims Industrial Applicability (IA) Industrial Applicability (IA) Claims Industrial Applicability (IA) Indust	ity;
Inventive Step (IS) Claims Claims Claims Industrial Applicability (IA) Claims Claims Claims Claims Claims Claims I-1+ NONE Claims 1-14 NONE Claims 1-14 NONE Claims 1-1+ lack an inventive step under PCT Article 35(3) as being obvious over Thurn et al. (US 6,00+,558), in Mazer et al. (US 5,707,358). Thurn teaches a pharmaceutical composition comprising an extract of iosoflavone with one or more pharmaceutical acceptable carriers, excipients, auxiliaries, and/or diluents (column 2, lines 14-63). The composition is for oral administration including tablets, capsules, powder or granules (column 4, lines 42-45). Suitable carriers are disclosed column 4, lines 65 through column 5, lines 1-32. The process for obtaining the composition is disclosed in column 24-43. The reference is silent as to the teaching of the controlled release of active ingredient. Mazer teaches a controlled release composition for oral administration including tablets, capsules, or granules that coated to provide sustained or delayed release(column 10, lines 55 through column 11, lines 1-40). The compositio comprising one or more beneficial agents including iso-flavone (column 13, lines 1-55). Thus, it would have been facile obvious for one of the ordinary skill in the art to modify Thurn's composition with the coating in view of the of Mazer to obtain a desire rate of release of active agent. The skilled artisan in this art would have been motivat prepare a controlled release composition to achieve high bioavailability of the active agent. NEW CITATIONS—— NEW CITATIONS——	
Inventive Step (IS) Claims Claims NONE Industrial Applicability (IA) Claims Claims Claims Claims Claims Claims Claims Industrial Applicability (IA) Claims Claim	YE
Industrial Applicability (IA) Claims NONE Claims Claims Claims Claims Claims Claims NONE Claims Cla	NO
Industrial Applicability (IA) Claims 1-14 NONE Claims Cla	_
Industrial Applicability (IA) Claims	YE
Claims Claims NONE Claims 1-14 lack an inventive step under PCT Article 33(3) as being obvious over Thurn et al. (US 6,004,558), in Mazer et al. (US 5,707,353). Thurn teaches a pharmaceutical composition comprising an extract of iosoflavone with one or more pharmaceutical acceptable carriers, excipients, auxiliaries, and/or diluents (column 2, lines 14-63). The composition is for oral administration including tablets, capsules, powder or granules (column 4, lines 42-45). Suitable carriers are disclos column 4, lines 65 through column 5, lines 1-32. The process for obtaining the composition is disclosed in column 24-43. The reference is silent as to the teaching of the controlled release of active ingredient. Mazer teaches a controlled release composition for oral administration including tablets, capsules, or granules that coated to provide sustained or delayed release(column 10, lines 55 through column 11, lines 1-40). The compositic comprising one or more beneficial agents including iso-flavone (column 13, lines 1-55). Thus, it would have been facie obvious for one of the ordinary skill in the art to modify Thurn's composition with the coating in view of the of Mazer to obtain a desire rate of release of active agent. The skilled artisan in this art would have been motivat prepare a controlled release composition to achieve high bioavailability of the active agent. NONE	NO
Claims NONE Claims 1-14 lack an inventive step under PCT Article 33(3) as being obvious over Thurn et al. (US 6,00+,558), in Mazer et al. (US 5,707,353). Thurn teaches a pharmaceutical composition comprising an extract of iosoflavone with one or more pharmaceutical acceptable carriers, excipients, auxiliaries, and/or diluents (column 2, lines 14-63). The composition is for oral administration including tablets, capsules, powder or granules (column 4, lines 42-45). Suitable carriers are disclosed column 4, lines 65 through column 5, lines 1-32. The process for obtaining the composition is disclosed in column 24-43. The reference is silent as to the teaching of the controlled release of active ingredient. Mazer teaches a controlled release composition for oral administration including tablets, capsules, or granules that coated to provide sustained or delayed release(column 10, lines 55 through column 11, lines 1-40). The compositio comprising one or more beneficial agents including iso-flavone (column 15, lines 1-55). Thus, it would have been facie obvious for one of the ordinary skill in the art to modify Thurn's composition with the coating in view of the of Mazer to obtain a desire rate of release of active agent. The skilled artisan in this art would have been motivat prepare a controlled release composition to achieve high bioavailability of the active agent. NONE	YE
Claims 1-14 lack an inventive step under PCT Article 33(3) as being obvious over Thurn et al. (US 6,004,558), in Mazer et al. (US 5,707,353). Thurn teaches a pharmaceutical composition comprising an extract of iosoflavone with one or more pharmaceutical acceptable carriers, excipients, auxiliaries, and/or diluents (column 2, lines 14-63). The composition is for oral administration including tablets, capsules, powder or granules (column 4, lines 42-45). Suitable carriers are disclosed column 4, lines 65 through column 5, lines 1-32. The process for obtaining the composition is disclosed in column 24-43. The reference is silent as to the teaching of the controlled release of active ingredient. Mazer teaches a controlled release composition for oral administration including tablets, capsules, or granules that coated to provide sustained or delayed release(column 10, lines 55 through column 11, lines 1-40). The composition comprising one or more beneficial agents including iso-flavone (column 13, lines 1-55). Thus, it would have been facie obvious for one of the ordinary skill in the art to modify Thurn's composition with the coating in view of the of Mazer to obtain a desire rate of release of active agent. The skilled artisan in this art would have been motivate prepare a controlled release composition to achieve high bioavailability of the active agent.	NO
NONE .	teaching
·	

International application No.

PCT/IL00/00494

Su	nnl	emen	tai	Box

(To be used when the space in any of the preceding boxes is not sufficient)

Continuation of: Boxes I - VIII

Sheet 10

CLASSIFICATION:

The International Patent Classification (IPC) and/or the National classification are as listed below: IPC(7): A61K 9/16, 9/20, 9/22, 9/26, 9/48, 9/52, 9/54, 9/56, 9/58, 9/64; A01N 25/00 and US Cl.: 424/451, 453, 457, 458, 459, 461, 462, 464, 465, 468, 469, 470, 490, 494, 497; 514/783

INTERNATIONAL SEARCH REPORT

Form PCT/ISA/210 (second sheet) (July 1998)*

International application No.
PCT/IL00/00494

A. CLASSIFICATION OF SUBJECT MATTER			
IPC(7) :Please See Extra Sheet. US CL :Please See Extra Sheet.			
According to International Patent Classification (IPC) or to bo	th national classification and IPC		
B. FIELDS SEARCHED	,		
Minimum documentation searched (classification system follow	ed by classification symbols)		
U.S. : 424/451, 453, 457, 458, 459, 461, 462, 464, 465, 46	8, 469, 470, 490, 494, 497; 514/783		
Documentation searched other than minimum documentation t			
searched	the extent that such documents are included in the neids		
Electronic data base consulted during the international search (West	name of data base and, where practicable, search terms used)		
C. DOCUMENTS CONSIDERED TO BE RELEVANT			
Category* Citation of document, with indication, where a	ppropriate, of the relevant passages Relevant to claim No.		
Y US 6,004,558 A (THURN et al.) 21 D lines 14-63; column 3, lines 19 thr column 5, lines 1-60, column 7, lines	ough column 4, lines 1-64;		
lines 12-62; column 10, lines 55 thr	US 5,707,353 A (MAZER et al.) 13 January 1998; see column 9, lines 12-62; column 10, lines 55 through column 11, lines 1-40; column 12, lines 66 through column 13, lines 1-55.		
Further documents are listed in the continuation of Box	C. See patent family annex.		
* Special categories of cited documents: "I" later document published after the international filing date or priority			
"A" document defining the general state of the art which is not considered	date and not in conflict with the application but cited to understand the principle or theory underlying the invention		
to be of particular relevance "X" document of particular relevance; the claimed invention cannot be carlier document published on or after the international filing date "X" document of particular relevance; the claimed invention cannot be			
Considered novel or cannot be considered to involve an inventive step "L" document which may throw doubts on priority claim(s) or which is "L" document which may throw doubts on priority claim(s) or which is			
cited to establish the publication date of another citation or other special reason (as specified) "Y" document of particular relevance; the claimed invention cannot be considered to involve an invention stanged to invention stang			
considered to involve an inventive step when the document is combined "O" document referring to an oral disclosure, use, exhibition or other with one or more other such documents, such combination being obvious to a person skilled in the art			
*P document published prior to the international filling date but later a document member of the same patent family than the priority date claimed			
Date of the actual completion of the international search Date of mailing of the international search report			
24 JAN 2001			
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Authorized officer Authorized officer Authorized officer Papal Ford Special ST Authorized officer			
Box PCT Washington, D.C. 20231	SUSAN TRANS PARALEGAL SPECIALIST		
Facsimile No. (703) 305-3230	Telephone No. (703) 308-1235		

INTERNATIONAL SEARCH REPORT

International application No. PCT/IL00/00494

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)
This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
2. Claims Nos.: because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)
This International Searching Authority found multiple inventions in this international application, as follows:
Please See Extra Sheet.
As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. X No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.: 1-14
Remark on Protest The additional search fees were accompanied by the applicant's protest. No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No. PCT/IL00/00494

A. CLASSIFICATION OF SUBJECT MATTER: IPC (7):

A61K 9/16, 9/20, 9/22, 9/26, 9/48, 9/52, 9/54, 9/56, 9/58, 9/64; A01N 25/00

A. CLASSIFICATION OF SUBJECT MATTER: US CL $\,:\,$

424/451, 453, 457, 458, 459, 461, 462, 464, 465, 468, 469, 470, 490, 494, 497; 514/783

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions, and which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

Group I, claim(s) 1-14, drawn to a controlled release formulation of isoflavone-enriched fraction or mixture thereof. Group II, claim(s) 15-32, drawn to a controlled release formulation of isoflavone-enriched fraction or mixture thereof coated with film comprising water soluble polymer and water insoluble polymer.

The inventions listed as Groups I and II do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: they do not share the same essential feature element(s) that define the "special technical feature" necessary to specify a contribution over the prior art. The feature common to all the groups is granulated isoflavone which is known in the art and, therefore, cannot be said to be the special technical feature which makes a contribution over the prior art. All other features differ from each other, in example, coating granulate, tablet, capsule, each of which are known in the prior art. Thus, these claims lack the corresponding special technical feature(s) necessary to link them together to fulfill the Unity of Invention requirement.